Vestal Point Capital LP Has $33.08 Million Holdings in Savara Inc (NASDAQ:SVRA)

Vestal Point Capital LP lifted its stake in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 33.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,775,000 shares of the company's stock after acquiring an additional 2,685,000 shares during the quarter. Savara comprises approximately 2.0% of Vestal Point Capital LP's holdings, making the stock its 20th largest position. Vestal Point Capital LP owned about 6.28% of Savara worth $33,079,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rosalind Advisors Inc. bought a new stake in Savara during the fourth quarter valued at about $8,151,000. Nantahala Capital Management LLC lifted its position in shares of Savara by 45.2% during the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock worth $23,103,000 after purchasing an additional 2,344,308 shares during the last quarter. Emerald Advisers LLC bought a new stake in Savara during the 4th quarter valued at approximately $7,161,000. Farallon Capital Management LLC grew its holdings in Savara by 49.9% in the 4th quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock valued at $20,983,000 after buying an additional 2,275,000 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its holdings in Savara by 23.2% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock valued at $24,449,000 after buying an additional 1,498,223 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $6.00 price objective on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Savara currently has a consensus rating of "Moderate Buy" and an average price target of $8.83.

Savara Stock Performance

Shares of SVRA traded up $0.02 on Thursday, reaching $2.93. 919,170 shares of the stock traded hands, compared to its average volume of 1,304,090. The stock's 50-day moving average price is $2.97 and its 200-day moving average price is $3.01. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market cap of $506.41 million, a price-to-earnings ratio of -6.81 and a beta of 0.44. Savara Inc has a 12 month low of $2.26 and a 12 month high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). Equities analysts forecast that Savara Inc will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.